Article
A novel davunetide (NAPVSIPQ Q to NAPVSIPQ E ) point mutation in activity‐dependent neuroprotective protein (ADNP) causes a mild developmental syndrome
20 Jan 2023
Abstract excerpt
NAP (NAPVSIPQ, drug candidate name, davunetide) is the neuroprotective fragment of activity-dependent neuroprotective protein (ADNP). Recent studies identified NAPVSIP as a Src homology 3 (SH3) domain-ligand association site, responsible for controlling signalling pathways regulating the cytoskeleton. Furthermore, the SIP motif in NAP/ADNP was identified as crucial for direct microtubule end-binding protein...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
